Skip to main content
PharmaSGP Holding SE logo

PharmaSGP Holding SE — Investor Relations & Filings

Ticker · PSG ISIN · DE000A2P4LJ5 LEI · 3912005CZ12PVVCIPT91 F Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2025-04-15 Earnings Release
Country DE Germany
Listing F PSG

About PharmaSGP Holding SE

https://pharmasgp.com/english/

PharmaSGP Holding SE is a pharmaceutical company specializing in the development and marketing of a broad portfolio of over-the-counter (OTC) drugs and other healthcare products. The company focuses on pharmacy-exclusive products for chronic indications, primarily utilizing natural active ingredients with a favorable side-effect profile. It holds a market-leading position in several therapeutic areas, particularly in systemic, chemical-free pain remedies with its RubaXX® (rheumatic pain) and Restaxil® (nerve pain) brand families. The portfolio also includes prominent brands such as Baldriparan® (natural sleep aid), Formigran® (migraine), Spalt® (general pain), and DESEO® and NERADIN® (sexual weakness).

Recent filings

Filing Released Lang Actions
PharmaSGP with significant increase in revenues and EBITDA in 2024
Earnings Release Classification · 100% confidence The document is a corporate news release dated April 15, 2025, titled "PharmaSGP with significant increase in revenues and EBITDA in 2024." It presents preliminary, unaudited financial figures for the 2024 financial year, including revenues (€ 118.8 million) and adjusted EBITDA (€ 37.2 million), along with management commentary and a forecast for 2025. This content structure—announcing key financial highlights immediately after the period ends, often before the full audited report—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) because it explicitly states the full annual report will be published later (April 30, 2025). It is too detailed for just a Report Publication Announcement (RPA) as it contains the actual preliminary results and commentary. FY 2024
2025-04-15 English
Q3 statement / Q3 financial report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report covering the first nine months (9M) of 2024 for PharmaSGP. It includes detailed financial performance analysis, revenue breakdowns, earnings development, asset/liability positions, and condensed interim consolidated financial statements as of 30 September 2024. It is not a mere announcement or certification, but the actual interim report containing substantive financial data. 9M 2024
2024-11-29 English
Q3 statement / Q3 financial report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report covering the first nine months (9M) of 2024 for PharmaSGP. It includes detailed financial performance analysis, revenue breakdowns, earnings development, asset/liability positions, and condensed interim consolidated financial statements as of 30 September 2024. It is not a mere announcement or certification, but the actual interim report containing substantive financial data. 9M 2024
2024-11-28 English
Q3 statement / Q3 financial report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report covering the nine-month period ending September 30, 2024. It includes detailed financial performance analysis, management commentary on business trends, and condensed interim consolidated financial statements. It is not a short announcement or a certification, but a substantive report containing actual financial data, fitting the definition of an Interim/Quarterly Report. 9M 2024
2024-11-28 English
PharmaSGP Holding SE: FUTRUE GmbH, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of the associated person (Dr. Clemens Fischer), their position, and the nature of the transaction (Acquisition of shares) including price and volume. This content directly matches the definition for Director's Dealing.
2024-11-25 English
CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025
Board/Management Information Classification · 100% confidence The document is a formal announcement dated November 5, 2024, detailing a change in the Chief Executive Officer (CEO) position at PharmaSGP Holding SE, effective January 1, 2025. It explicitly states the succession plan and includes quotes from the outgoing CEO, the incoming CEO, and the Chairman of the Supervisory Board. This content directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2024-11-05 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.